Every 10-Q that Briacell Therapeutics Corp. (BCTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTX filings page.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerated cancer immunotherapy development. For the nine months ended April 30, 2026, the company lost $22.8 million, up from $18.4 million a year earlier, driven mainly by higher research, development, and clinical trial expenses of $18.7 million versus $14.2 million.
Cash, cash equivalents, and short-term investments totaled $22.8 million, with cash of $6.9 million and positive working capital of $21.8 million. However, a cumulative deficit of $134.3 million and operating cash outflows of $22.7 million over nine months led management to state that substantial doubt exists about BriaCell’s ability to continue as a going concern without additional financing.
Clinically, BriaCell advanced its Bria-IMT™ pivotal Phase 3 study in metastatic breast cancer under FDA Fast Track Designation, reporting extended survival and favorable safety signals, and broadened its pipeline with Bria-OTS™, Bria-OTS+™, and Bria-PROS+™ including new FDA clearance to begin a Phase 1/2a study for Bria-BRES+™.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerates late-stage cancer trials. For the three months ended January 31, 2026, net loss was $7.3M versus $6.3M a year earlier, driven mainly by higher research and development spending.
Research, development, and clinical trial expenses for the half-year rose to $12.7M from $9.4M, reflecting intensive investment in the pivotal Phase 3 Bria‑IMT™ metastatic breast cancer study and the Bria‑OTS™ Phase 1/2a program. General and administrative costs were relatively stable at $3.1M for the six-month period.
The company strengthened its balance sheet, ending January 31, 2026 with cash and cash equivalents of $29.9M and positive working capital of $29.0M, helped by $27.9M in net equity financing during the half-year and a public offering of approximately $30.0M in gross proceeds. However, accumulated deficit reached $127.2M, and management states that uncertainty around securing future financing raises substantial doubt about BriaCell’s ability to continue as a going concern.
BriaCell Therapeutics Corp. reported results for the quarter ended October 31, 2025, as it advances multiple immuno-oncology programs, including its pivotal Phase 3 Bria‑IMT™ trial in metastatic breast cancer and the Bria‑OTS™ off‑the‑shelf platform.
The company posted a net loss of $8.3 million versus $5.8 million a year earlier, driven mainly by research and development expenses that rose to $6.7 million from $3.7 million. Clinical trial costs reached $4.9 million, including $3.8 million for the Bria‑IMT™ pivotal Phase 3 study and $1.0 million for the Bria‑OTS™ Phase 1/2a trial. General and administrative expenses were $1.6 million, and basic and diluted loss per share was $4.35.
Liquidity tightened: cash and cash equivalents were $2.7 million and short‑term investments $7.5 million, for total assets of $13.1 million and working capital of $8.0 million. Operating cash outflow was $7.7 million in the quarter, shareholders’ equity fell to $9.4 million, and the accumulated deficit reached $119.95 million. Management notes that recurring losses, negative cash flows and reliance on new financings cast substantial doubt on BriaCell’s ability to continue as a going concern, despite having raised $50.9 million of gross equity proceeds in the prior fiscal year and securing a $2.0 million NCI SBIR grant for Bria‑PROS+™.
Operationally, BriaCell continued enrolling its pivotal Bria‑IMT™ Phase 3 trial at 79 U.S. sites, under FDA Fast Track designation, with a fourth consecutive positive Data Safety Monitoring Board recommendation. The company highlighted prior Phase 2 data showing median overall survival of 13.4–16.5 months in metastatic breast cancer cohorts versus 6.7–9.8 months reported in the literature, and indicated that top‑line Phase 3 data and an interim overall survival analysis could be available as early as the first half of 2026, subject to event accrual. BriaCell also advanced its Bria‑OTS+™ platform through preclinical results and a collaboration with Memorial Sloan Kettering’s Therapeutics Accelerator, and expanded a small‑molecule oncology pipeline via BriaPro’s AI‑driven collaboration with Receptor.AI.